Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Other COVID-19 Vaccine Race: GSK Leads In Adjuvant Field, But Dynavax And Novavax Making Moves

Executive Summary

The certainty that any COVID-19 vaccine will see demand outstrip supply could be an inflection point for the once-quiet field of novel vaccine adjuvant research, which promises to enhance immune response and lower the vaccine dose required.

You may also be interested in...



GSK Eases Cervarix Out Of India, Eyes On Trajectory Of Synflorix

GSK discontinues Cervarix in India as part of portfolio rationalization efforts against the backdrop of the arrival of Serum’s 'affordable' quadrivalent HPV vaccine. The heat is also believed to be on the UK drugmaker’s pneumococcal vaccine Synflorix in the country.

TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens

The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and pancreatic settings where immuno-oncology has shown moderate efficacy or less.

Vaccine Adjuvant Heightens Panel’s Worries About Rare Adverse Events With Heplisav

FDA’s Vaccines and Related Biological Products Advisory Committee recommended 8 to 5 with one abstention that Dynavax acquire more safety data pre-licensure for its hepatitis B vaccine.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel